View Document Preview and Link Document Date: 2014-12-22 14:34:38 Open Document File Size: 63,78 KB Share Result on Facebook
Facility FDA’s Center / / IndustryTerm therapeutics for hepatitis C / drug product / energy / / MedicalCondition viral disease / participant’s HCV infection / liver cancer / diseases / disease / infection / liver failure / advanced liver disease / chronic HCV infection / inflammation / cirrhosis / chronic hepatitis C / Hepatitis C / HCV / itching / / Organization FDA / office of Antimicrobial Products / FDA’s Center for Drug Evaluation and Research / U.S. Food and Drug Administration / Centers for Disease Control and Prevention / / Person Edward Cox / / Position director / / Product ribavirin / / Technology genotype / / SocialTag 
Abbvie Drugs Approved by FDA December 19, 2014 The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with c